These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 21726959)
1. Activity and resistance of trastuzumab according to different clinical settings. Tagliabue E; Campiglio M; Pupa SM; Ménard S; Balsari A Cancer Treat Rev; 2012 May; 38(3):212-7. PubMed ID: 21726959 [TBL] [Abstract][Full Text] [Related]
2. The HER2 World: Better Treatment Selection for Better Outcome. Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S J Natl Cancer Inst Monogr; 2011; 2011(43):82-5. PubMed ID: 22043048 [TBL] [Abstract][Full Text] [Related]
3. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889 [TBL] [Abstract][Full Text] [Related]
4. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935 [TBL] [Abstract][Full Text] [Related]
5. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460 [TBL] [Abstract][Full Text] [Related]
7. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Menendez JA; Vellon L; Lupu R Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499 [TBL] [Abstract][Full Text] [Related]
8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
10. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Spector NL; Blackwell KL J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552 [TBL] [Abstract][Full Text] [Related]
11. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613 [TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051 [TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Chang HR Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392 [TBL] [Abstract][Full Text] [Related]
14. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813 [TBL] [Abstract][Full Text] [Related]
16. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003 [TBL] [Abstract][Full Text] [Related]
17. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195 [TBL] [Abstract][Full Text] [Related]
18. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537 [TBL] [Abstract][Full Text] [Related]
19. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283 [TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]